1
|
Rahimi A, Simmons A, Kim DN, Leitch M, Haas J, Gu X, Ahn C, Gao A, Spangler A, Morgan HE, Goudreau S, Seiler S, Farr D, Wooldridge R, Haley B, Bahrami S, Neufeld S, Mendez C, Alluri P, Rao R, Timmerman RD. Preliminary Results of Multi-Institutional Phase 1 Dose Escalation Trial Using Single-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2021; 112:663-670. [PMID: 34710523 DOI: 10.1016/j.ijrobp.2021.10.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 10/05/2021] [Accepted: 10/12/2021] [Indexed: 12/27/2022]
Abstract
PURPOSE We report on our early experience of our prospective multicenter phase 1 dose- escalation study of single-fraction stereotactic partial breast irradiation (S-PBI) for early stage breast cancer after partial mastectomy using a robotic stereotactic radiation system. METHODS AND MATERIALS Thirty women with in situ or invasive breast cancer stage 0, I, or II with tumor size <3 cm treated with lumpectomy were enrolled in this phase 1 single-fraction S-PBI dose-escalation trial. Women received either 22.5, 26.5, or 30 Gy in a single fraction using a robotic stereotactic radiation system. The primary outcome was to reach tumoricidal dose of 30 Gy in a single fraction to the lumpectomy cavity without exceeding the maximum tolerated dose. Secondary outcomes were to determine dose-limiting toxicity and cosmesis. Tertiary goals were ipsilateral breast recurrence rate, distant disease-free interval, recurrence-free survival, and overall survival. RESULTS From June 2016 to January 2021, 11, 8, and 10 patients were treated to doses of 22.5, 26.5, or 30 Gy in a single fraction, respectively, with median follow-up being 47.9, 25.1, and 16.2 months. No patients experienced acute (<90 days) grade 3 or higher treatment-related toxicity, and maximum tolerated dose was not reached. There were 2 delayed grade 3 toxicities. Four patients (13.8%) developed fat necrosis across all 3 cohorts, which compares favorably with results from other PBI trials. No dose cohort had a statistically significant cosmetic detriment from baseline to 12 months or 24 months follow-up by patient- or physician-reported global cosmetic scores. There were no reports of disease recurrence. CONCLUSIONS This phase 1 trial demonstrates that S-PBI can be used to safely escalate dose to 30 Gy in a single fraction with low toxicity and without detriment in cosmesis relative to baseline.
Collapse
Affiliation(s)
- Asal Rahimi
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas.
| | - Ambrosia Simmons
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - D Nathan Kim
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Marilyn Leitch
- Departments of Radiation Surgery, University Texas Southwestern Medical Center, Dallas, Texas
| | - Jonathan Haas
- Perlmutter Cancer Center at NYU Langone Hospital, Long Island, New York
| | - Xuejun Gu
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Chul Ahn
- Departments of Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Ang Gao
- Departments of Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Ann Spangler
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Howard E Morgan
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Sally Goudreau
- Departments of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Stephen Seiler
- Departments of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Deborah Farr
- Departments of Radiation Surgery, University Texas Southwestern Medical Center, Dallas, Texas
| | - Rachel Wooldridge
- Departments of Radiation Surgery, University Texas Southwestern Medical Center, Dallas, Texas
| | - Barbara Haley
- Departments of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Shohreh Bahrami
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Sarah Neufeld
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | | | - Prasanna Alluri
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| | - Roshni Rao
- Columbia University Medical Center, Breast Surgery, New York City, New York
| | - Robert D Timmerman
- Departments of Radiation Oncology, University Texas Southwestern Medical Center, Dallas, Texas
| |
Collapse
|
2
|
Fekrmandi F, Panzarella T, Dinniwell RE, Helou J, Levin W. Predictive factors for persistent and late radiation complications in breast cancer survivors. Clin Transl Oncol 2019; 22:360-369. [PMID: 31123988 DOI: 10.1007/s12094-019-02133-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Accepted: 05/11/2019] [Indexed: 02/02/2023]
Abstract
PURPOSE With improved diagnostic techniques and treatments of breast cancer, overall survival times are longer, giving more opportunity for normal tissue complications of treatment to manifest. Radiation late effects (RLEs) could have profound long-term impacts on the quality of life of the survivors. The aim of this study was to identify predictive factors influencing timing and types of complications in patients referred to the Adult Radiation Late Effects Clinic (ARLEC). METHODS In a period of 16 years, 296 breast cancer patients were referred to the ARLEC. The clinical records were retrospectively studied to collect epidemiologic, medical and treatment data. Associations were sought between candidate predictive factors and time to the first complication after radiation treatment (RT) completion (primary outcome), and pain or swelling (secondary outcomes) using univariable and multivariable linear and logistic regression analyses. All analyses were performed in SAS, version 9.4. RESULTS All patients were female with a mean age of 56.3 years. The first treatment-related complication occurred after a median of 3 months. Patients were followed at ARLEC for a median of 18 months. Older age and delay from surgery to RT (S-RT delay) were associated with earlier onset of complications (both p < 0.001). The most common complications were breast pain (62.1%) and swelling (45.9%). Histology and RT boost were associated with pain (p = 0.035 and 0.013). RT boost and S-RT delay on the other hand were associated with swelling (p = 0.013 and 0.005). CONCLUSIONS Clinical factors identified could help recognize the patients at high risk for developing RLEs and alert physicians to initiate earlier diagnostic and therapeutic measures.
Collapse
Affiliation(s)
- F Fekrmandi
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 700 University Avenue, Toronto, ON, M5G 1Z5, Canada
| | - T Panzarella
- Biostatistics Department, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - R E Dinniwell
- Department of Radiation Oncology, London Regional Cancer Program, Western University, London, Canada
| | - J Helou
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 700 University Avenue, Toronto, ON, M5G 1Z5, Canada
| | - W Levin
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 700 University Avenue, Toronto, ON, M5G 1Z5, Canada.
| |
Collapse
|
3
|
Wang K, Yee C, Tam S, Drost L, Chan S, Zaki P, Rico V, Ariello K, Dasios M, Lam H, DeAngelis C, Chow E. Prevalence of pain in patients with breast cancer post-treatment: A systematic review. Breast 2018; 42:113-127. [DOI: 10.1016/j.breast.2018.08.105] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 08/08/2018] [Accepted: 08/27/2018] [Indexed: 12/12/2022] Open
|
4
|
van la Parra RFD, Liao K, Smith BD, Yang WT, Leung JWT, Giordano SH, Kuerer HM. Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer. JAMA Surg 2018; 153:559-568. [PMID: 29387884 PMCID: PMC5875371 DOI: 10.1001/jamasurg.2017.5572] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 10/19/2017] [Indexed: 12/14/2022]
Abstract
Importance No comprehensive data are available regarding the frequency of breast biopsies performed during follow-up of treatment for invasive breast cancer. Objective To determine how often patients treated for breast cancer require breast biopsies during follow-up. Design, Setting, and Participants This nationwide population-based cohort study included 41 510 patients 64 years or younger in a commercial insurance database and 80 369 patients 66 years or older in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Patients were diagnosed with incident invasive breast cancer (stages I-III) from January 1, 2000, through December 31, 2011. Diagnosis and procedural codes were used to identify biopsy rates during follow-up. Data were analyzed from March 3 through October 3, 2017. Main Outcomes and Measures Cumulative incidence and adjusted risk of breast biopsy and subsequent breast cancer treatment were calculated using the Kaplan-Meier method and Cox proportional hazards regression. All statistical tests were 2 sided. Results Among the 121 879 patients in the study population, 5- and 10-year overall incidences of breast biopsy were 14.7% and 23.4%, respectively, in the commercial insurance cohort and 11.8% and 14.9%, respectively, in the SEER-Medicare cohort. The 5-year estimated incidence of breast biopsy was higher among women treated with brachytherapy (24.0% in the commercial insurance and 25.0% in the SEER-Medicare cohorts) than among those treated with whole-breast irradiation (16.7% in the commercial insurance and 15.1% in the SEER-Medicare cohorts) and persisted after multivariate adjustment in the commercial insurance (hazard ratio [HR], 1.53; 95% CI, 1.38-1.70; P < .001) and SEER-Medicare (HR, 1.76; 95% CI, 1.63-1.91; P < .001) cohorts. Adjuvant chemotherapy use (HR, 1.31; 95% CI, 1.25-1.37; P < .001) and patient age (>85 vs 66-69 years; HR, 0.40; 95% CI, 0.36-0.44; P < .001) in the SEER-Medicare cohort and endocrine therapy in the commercial insurance (HR, 0.88; 95% CI, 0.82-0.93; P < .001) and SEER-Medicare (HR, 0.91; 95% CI, 0.85-0.97; P = .002) cohorts were independently associated with biopsy. After unilateral mastectomy, the estimated 5-year contralateral breast biopsy rates were 10.4% and 7.7% in the commercial insurance and SEER-Medicare cohorts, respectively. Of the patients with breast biopsy, 1239 of 4158 patients (29.8%) in the commercial insurance cohort and 2258 of 9747 patients (23.2%) in the SEER-Medicare cohort underwent subsequent cancer treatment. Conclusions and Relevance These data on the need for breast biopsies during follow-up and subsequent treatments from a large cohort of women with commercial insurance and Medicare can be used in the context of therapy-planning discussions and survivorship expectations for patients with breast cancer.
Collapse
Affiliation(s)
- Raquel F. D. van la Parra
- Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kaiping Liao
- Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Benjamin D. Smith
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Wei T. Yang
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jessica W. T. Leung
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sharon H. Giordano
- Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Henry M. Kuerer
- Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
5
|
Abbott AM, Valente SA, Loftus L, Tendulkar RD, Greif JM, Bethke KP, Donnelly ED, Lottich C, Ross DL, Friedman NB, Bedi CG, Joh JE, Kelemen P, Hoefer RA, Kang SK, Ruffer J, Police A, Fyles A, Graves GM, Willey SC, Tousimis EA, Small W, Lyons J, Grobmyer S, Laronga C. A multi-institutional analysis of intraoperative radiotherapy for early breast cancer: Does age matter? Am J Surg 2017; 214:629-633. [PMID: 28918848 DOI: 10.1016/j.amjsurg.2017.06.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 06/19/2017] [Accepted: 06/20/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND Single-session intraoperative radiation therapy (IORT) minimizes treatment demands associated with traditional whole breast radiation therapy (WBRT) but outcomes on local disease control and morbidity among the elderly is limited. METHODS A multi-institutional retrospective registry was established from 19 centers utilizing IORT from 2007 to 2013. Patient, tumor, and treatment variables were analyzed for ages <70 and ≥70. RESULTS We evaluated 686 patients (<70 = 424; ≥70 = 262) who were margin and lymph node negative. Patients <70 were more likely to have longer operative time, oncoplastic closure, higher rates of IORT used as planned boost, and receive chemotherapy and post-operative WBRT. Wound complication rates were low and not significantly different between age groups. Median follow-up was 1.06 (range 0.51-1.9) years for < 70 and 1.01 (range 0.5-1.68) years for ≥ 70. There were 5 (0.73%) breast recurrences (4 in <70 and 1 ≥ 70, p = 0.65) and no axillary recurrences during follow-up. CONCLUSIONS IORT was associated with a low rate of wound complication and local recurrence on short-term follow-up in this cohort.
Collapse
Affiliation(s)
| | | | - L Loftus
- Moffitt Cancer Center, Tampa, USA
| | | | - J M Greif
- Alta Bates Summit Medical Center, Oakland, CA, USA
| | | | | | - C Lottich
- Community Physician Network Breast Care, Community Health Network, Indianapolis, IN, USA
| | - D L Ross
- Community Physician Network Breast Care, Community Health Network, Indianapolis, IN, USA
| | | | - C G Bedi
- Mercy Medical Center, Baltimore, MD, USA
| | - J E Joh
- Mercy Medical Center, Baltimore, MD, USA
| | - P Kelemen
- Ashikari Breast Center, Dobbs Ferry, NY, USA
| | - R A Hoefer
- The Sentara Dorothy G. Hoefer Comprehensive Breast Center, Newport News, VA, USA
| | - S K Kang
- The Sentara Dorothy G. Hoefer Comprehensive Breast Center, Newport News, VA, USA
| | - J Ruffer
- Advocate Good Shepherd Hospital, Barrington, IL, USA
| | - A Police
- University of California Irvine Medical Center, Irvine, CA, USA
| | - A Fyles
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - G M Graves
- Sutter Cancer Center, Sacramento, CA, USA
| | - S C Willey
- MedStar Georgetown University Hospital, Washington, DC, USA
| | - E A Tousimis
- MedStar Georgetown University Hospital, Washington, DC, USA
| | - W Small
- Loyola University, Maywood, IL, USA
| | - J Lyons
- The Cleveland Clinic, Cleveland, OH, USA
| | - S Grobmyer
- The Cleveland Clinic, Cleveland, OH, USA
| | | |
Collapse
|
6
|
Wallace AS, Tchatalbachev V, Nelson J, Wang Z, Dale P, Biedermann GB. Long term radiographic findings of breast brachytherapy: Implications of surgical volume. J Surg Oncol 2017; 116:203-207. [PMID: 28445590 PMCID: PMC9744260 DOI: 10.1002/jso.24646] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 03/17/2017] [Indexed: 12/14/2022]
Abstract
PURPOSE Little is known about long-term radiographic findings after treatment with accelerated partial breast irradiation (APBI). METHODS Univariate and multivariate analysis of factors leading to formation and resolution of seroma were performed in patients treated with lumpectomy and APBI. RESULTS Post-treatment images of 129 patients were reviewed by one radiologist. Median surgical excision volume was 108.9 cc (range 20.5-681.9). Primary mode of imaging was mammogram. Median time from end of RT to first and last surveillance image was 6 and 54 months, respectively. Median number of images was 7 (range 3-12). Seroma was identified in 98 (76%) patients, with median maximum diameter of 3.9 cm. Forty (41%) patients experienced resolution of seroma, at a median time of 29 months (range 6-74). On univariate analysis, surgical excision volume was associated with seroma formation, and tumor stage and margin re-excision were significant on univariate and multivariate analysis. No factors were associated with seroma resolution. CONCLUSION Seroma formation after APBI resolves around 2.5 years for many patients, but persists for others possibly due to primary tumor and surgical excision volumes. With revised criteria on the definition of positive margins, smaller volumes may lead to decreased risk of seroma formation for future patients.
Collapse
Affiliation(s)
- Audrey S. Wallace
- University of Missouri School of Medicine, Columbia,Department of Radiation Oncology, University of Alabama Birmingham
| | | | - Jay Nelson
- University of Missouri School of Medicine, Columbia
| | - Zhenyu Wang
- Department of Radiology, University of Missouri, Columbia
| | - Paul Dale
- Division of Surgical Oncology, Navicent Healthcare & Mercer University School of Medicine
| | | |
Collapse
|
7
|
Holmes DR. Early complications after intraoperative radiotherapy revisited. J Surg Oncol 2017; 115:779-781. [DOI: 10.1002/jso.24590] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Accepted: 02/01/2017] [Indexed: 11/11/2022]
|
8
|
Shaitelman SF, Amendola B, Khan A, Beriwal S, Rabinovitch R, Demanes DJ, Kim LH, Cuttino L. American Brachytherapy Society Task Group Report: Long-term control and toxicity with brachytherapy for localized breast cancer. Brachytherapy 2017; 16:13-21. [DOI: 10.1016/j.brachy.2016.04.392] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Revised: 04/26/2016] [Accepted: 04/26/2016] [Indexed: 01/22/2023]
|
9
|
Tumoral Calcinosis: An Uncommon Cause for a Mass in a Reconstructed Breast. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN 2016; 4:e700. [PMID: 27579225 PMCID: PMC4995718 DOI: 10.1097/gox.0000000000000687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 03/01/2016] [Indexed: 11/26/2022]
Abstract
Tumoral calcinosis is a rare clinical and histopathological syndrome whose exact etiology is unknown. We present a case of a 57-year-old woman who presents with a painful lump in her right chest after bilateral breast reconstructions for bilateral asynchronous breast cancers. It is important to be aware of all possible differential diagnoses in a patient presenting with a chest mass after mastectomy and reconstruction for breast cancer as not all lesions of this type represent recurrent cancer.
Collapse
|
10
|
Hieken TJ, Mutter RW, Jakub JW, Boughey JC, Degnim AC, Sukov WR, Childs S, Corbin KS, Furutani KM, Whitaker TJ, Park SS. A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. Ann Surg Oncol 2016; 23:3297-303. [DOI: 10.1245/s10434-016-5321-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Indexed: 12/11/2022]
|
11
|
Zur M, Shai A, Leviov M, Bitterman A, Shiloni E, Ben Yosef R, Steiner M. Short-term complications of intra-operative radiotherapy for early breast cancer. J Surg Oncol 2016; 113:370-3. [DOI: 10.1002/jso.24157] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 12/22/2015] [Indexed: 11/10/2022]
Affiliation(s)
- Maoz Zur
- Department of Oncology; Lin and Carmel Lady Davis Medical Centers; Haifa Israel
| | - Ayelet Shai
- Department of Oncology; Galilee Medical Center; Nahariyya Israel
- Faculty of Medicine; Bar-Ilan University; Zefat Israel
| | - Michelle Leviov
- Department of Oncology; Lin and Carmel Lady Davis Medical Centers; Haifa Israel
| | - Arie Bitterman
- Department of Surgery A; Carmel Lady Davis Medical Center; Haifa Israel
| | - Eitan Shiloni
- Department of Surgery B; Carmel Lady Davis Medical Center; Haifa Israel
- Bruce Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Haifa Israel
| | - Rahamim Ben Yosef
- Bruce Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Haifa Israel
- Radiotherapy Unit; Oncology Institute; Rambam Health Care Campus; Haifa Israel
| | - Mariana Steiner
- Department of Oncology; Lin and Carmel Lady Davis Medical Centers; Haifa Israel
| |
Collapse
|
12
|
|